Last checked at 14 Sep 2020 07:00
14 September 2020
Avacta Group plc
("Avacta", the "Group" or the "Company")
Notice of Results and Investor Presentation
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its unaudited interim results for the 6 months ended 30 June 2020 on Monday, 28 September 2020.
Shareholder webinar
A shareholder and investor webinar presentation by Alastair Smith, Chief Executive Officer, Tony Gardiner, Chief Financial Officer and Neil Bell, Chief Development Officer will take place at 10:30 hrs on Monday, 28 September 2020.
The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform.
Avacta is committed to ensuring that there are appropriate communication structures for all elements of its shareholder base so that its strategy, business model and performance are clearly understood.
Investors can sign up to Investor Meet Company for free and then click "Add to meet" Avacta Group via the following link to join the webinar:
https://www.investormeetcompany.com/avacta-group-plc/register-investor
Investors who have already registered and clicked "Add to meet" Avacta Group plc, will be automatically invited.
· Investors are encouraged to submit questions pre-event via the Investor Meet Company Platform, once registered.
· Questions can be submitted pre-event via the "Ask a Question" function located on your Investor Meet Company dashboard, in addition questions can be submitted during the live event.
· Whilst the Company will not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications.
· Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.
· Investor feedback can also be submitted post the event on the Investor Meet Company platform to ensure the Company can understand the views of all elements of its shareholder base.
Analyst briefing
A sell-side analyst briefing given by Alastair Smith, Chief Executive Officer, Tony Gardiner, Chief Financial Officer and Neil Bell, Chief Development Officer, will be held by webcast presentation, followed by a Q&A session, at 09.00 hrs on Monday, 28 September 2020.
Pre-registration is required for attendance to the call. To confirm attendance, please email avacta@yellowjerseypr.com and you will be sent the link to join.
The presentation will be posted on the Company's website at the following address:
https://avacta.com/investors/documents-presentations
- Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd (Nominated Adviser and Joint Broker) Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern - ECM | Tel: +44 (0) 207 220 0500 www.finncap.com |
Zeus Capital Limited (Joint Broker) John Goold / Rupert Woolfenden - Corporate Broking
Yellow Jersey PR (Financial Media and IR) Sarah Hollins Henry Wilkinson
Zyme Communications (Trade and Regional Media) Katie Odgaard |
Tel: +44 (0)203 829 5000 www.zeuscapital.co.uk
Tel: +44 (0)203 004 9512 avacta@yellowjerseypr.com
Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com
|
About Avacta Group plc - https://www.avacta.com
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.
The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost.
Avacta's pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.
By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic later in 2020 or early 2021.
Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a deal with LG Chem worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and has established a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.
Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts